Pluristem Therapeutics (PSTI) receives FDA orphan status for aplastic anemia treatment
- Top 10 News for 2/8 - 2/12: Banks Crushed Amid Global Concerns; Tesla Ramps on Outlook; SEC Targets Boeing
- Republicans gear up for U.S. Supreme Court battle after Scalia's death
- Wall Street rallies; S&P 500 snaps five-day losing streak
- Loeb's Third Point LLC 13F Shows New Stake Axalta (AXTA), Morgan Stanley (MS), Liquidates T-Mobile (TMUS), Lowers eBay (EBAY) ...
- Intercept Pharma (ICPT) Said to Explore Sale Following Interest
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) has received FDA orphan status for aplastic anemia treatment.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pluristem Reports Second Quarter Fiscal 2016 Financial Highlights and Clinical Development Update
- CMS Adds Veltassa to CY16 Formulary Reference File; H.C. Wainwright Affirms Relypsa (RLYP) at 'Buy'
- Achillion Pharma (ACHN) Commences ACH-4471 Phase 1 as Complement Factor D Inhibitor
Create E-mail Alert Related CategoriesFDA, Insiders' Blog
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!